Takeda Pharmaceutical Company LimitedTAK

Where TAK's EV/EBITDA sits inside its own 10-year distribution, with the yearly high, low and average.

$20.01-0.14 (-0.69%)Previous close
NYSEHealthcare

TAK EV/EBITDA: current value, 10-year range and year-by-year history

EV/EBITDA History

Historically priceyAbove avgAround avgBelow avgHistorically cheap
TAK EV/EBITDA historyTAK EV/EBITDA from Oct 2023 to Sep 2026: low 8.35, high 11.18, latest 10.69.8.128.949.7710.5911.41Oct 23May 24Dec 24Jul 25Mar 26Sep 26med 9.63

TAK EV/EBITDA by year

Yearly range of TAK’s ev/ebitda from 2016 to 2026. Over the full period it ranged from 7.2 to 26.8, averaging 11.8.

TAK EV/EBITDA — yearly low, average, high and year-end values
YearLowAverageHighYear-end
20268.89.810.910.7
20258.89.410.68.8
20248.49.911.29.0
20238.79.310.29.4
20227.59.010.29.8
20217.29.413.07.5
202011.915.117.511.9
201914.620.226.817.1
20189.712.515.014.8
201710.413.015.013.5
20169.810.210.910.1

Get notified when TAK EV/EBITDA crosses a threshold

Free — one alert setup, notifications by push, Telegram, or Discord.

An acquisition-style valuation multiple: Enterprise Value (market cap + net debt) divided by operating earnings before accounting adjustments. Compares companies fairly regardless of their capital structure.

Formula(Market Cap + Net Debt) / EBITDA
Full guide
How to read this chart

Unlike P/E, this metric accounts for debt — two companies with identical operations but different leverage will show similar EV/EBITDA. Low vs history suggests the total business is modestly priced.

Key caveats
  • EBITDA ignores capital expenditure. For asset-heavy businesses (airlines, mining, utilities), this understates the real cost — use EV/EBIT or EV/FCF instead.
  • Large acquisitions temporarily spike net debt and can distort the ratio for 1–2 years during integration.
Pro — up to 30-year history

Unlock 10y, 15y, 20y, and 30y history with peer comparison and CSV export.